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The biopharmaceutical market is driving the revolution from batch to continuous manufacturing (CM) for higher 
productivity and lower cost. In this work, a bench-scale fully integrated continuous downstream process for 
monoclonal antibody production was established and successfully scaled up to 200 L scale. The process 
includes a continuous proteinA step, a viral inactivation step, a batch-wise cation exchange and anion exchange 
step, a batch-wise viral-filtration step, and a single-pass UF/DF step. An inline protein quantity monitoring 
system was designed to control protein loading mass on cation exchange column. All the steps were connected 
through surge tanks and integrated by DeltaVTM automatic control system. The setup was tested for the 
continuous production of a mAb, and the overall production process can be finished within 24 hours (Figure 1). 
Reproducible performances and product quality were observed over 3 lab batches (Figure 2). The process was 
then successfully scaled up to pilot plant (200 L, fed batch) with consistent results. The viral clearance study and 
lifetime study on Protein A step was designed with scale down model. This work demonstrates the feasibility 
and advantage of applying integrated continuous process in monoclonal antibody production and may provide a 
reference for large scale manufacturing. 
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